Inventiva ผลตอบแทนจากการลงทุน 2024

Inventiva ทำอะไร?

Inventiva SA is a biopharmaceutical company based in France that specializes in the development of novel therapies for various diseases. The company was founded in 2002 by Pierre Broqua and Frédéric Cren to develop innovative drugs based on research on the human genome. Inventiva's business model is to develop a pipeline of drug candidates and either sell them or bring them into partnerships with other companies. The company has built a broad portfolio of patents and license agreements that allow it to develop a variety of products. Inventiva's research and development focuses on three key areas: fibrosis, oncology, and autoimmune diseases. In these areas, the company has several product candidates in various stages of clinical development. Inventiva's products include Lanifibranor, a drug for the treatment of fatty liver disease, which is currently in Phase III trials. Additionally, the company has several compounds in its oncology pipeline, including IVA337, IVA336, and IVA339, all of which have shown promising results in preclinical studies. In the field of autoimmune diseases, Inventiva is working on a compound called ABBV-157, which is being developed in collaboration with Abbvie. This compound is intended to help reduce inflammation in patients with rheumatoid arthritis and psoriasis. Overall, Inventiva has made significant progress in recent years and has achieved important milestones in the development of its products. The company has also entered into several partnerships with major pharmaceutical and biotech companies to bring its products to market. In 2020, Inventiva took the next important step in its growth strategy by announcing a merger with American company AbbVie. The acquisition is expected to accelerate the development and commercialization of Inventiva's products and provide the company with a strong partner in the international market. However, Inventiva has not limited itself to drug development. The company has also developed a range of services to support other companies in the development of new drugs. These include laboratory services, protein purification and analysis, cell culture, and more, offered through their own contract research organization (CRO) unit. In summary, Inventiva is an emerging company with a strong portfolio of products and services. The company has done excellent work in developing new medical technologies in recent years and is likely to have even more success in the future with the acquisition by AbbVie. Inventiva เป็นหนึ่งในบริษัทที่ได้รับความนิยมมากที่สุดบน Eulerpool.com.